Newamsterdam pharma to participate at upcoming investor conferences in march

Naarden, the netherlands and miami, feb. 25, 2025 (globe newswire) -- newamsterdam pharma company n.v. (nasdaq: nams or “newamsterdam” or the “company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“cvd”) with elevated low-density lipoprotein cholesterol (“ldl-c”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:
NAMS Ratings Summary
NAMS Quant Ranking